Valley Interfaith in favor of Proposition 1

Translate to Spanish or other 102 languages!

Hidalgo County— Valley Interfaith in conjunction with Project VIDA will announce their endorsement of Proposition 1.

- Advertisement -

The organization says the hospital district will help the most vulnerable members of the community receive the healthcare services they need.

“There are so many reasons to support the creation of the hospital district, support Proposition 1. It is going to mean better access to healthcare and more clinics,” Valley Interfaith leader Eddie Anaya, said. “For every dollar invested, the federal government will match that dollar with $1.50. By leveraging our local monies, we can access millions of dollars and we won’t lose them to other counties.”

The organization plans to block walk in support of Proposition 1 and get the message out during Sunday mass at numerous churches across Hidalgo County.

- Advertisement -

Valley Interfaith is a broad based organization of over 25 institutions valley wide that works to develop community leaders so that our parishioners and families have a continuing voice and say in matters directly affecting their communities. We are strictly non-partisan and do not endorse political candidates.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -